Log In
BCIQ
Print this Print this
 

Zubsolv, buprenorphine/naloxone (OX219)

Also known as: formerly PKX219

  Manage Alerts
Collapse Summary General Information
Company Orexo AB
DescriptionSublingual tablet formulation of buprenorphine and naloxone
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationAddiction
Indication DetailsInduction treatment of opioid dependence; Maintenance treatment of opioid dependence; Treat opioid dependence
Regulatory Designation
PartnerMundipharma International Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/02/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today